squalamine   Click here for help

GtoPdb Ligand ID: 10861

Synonyms: 7alpha-Hydroxy, 3beta-spermidine | MSI-1256F (squalamine lactate)
Compound class: Synthetic organic
Comment: Squalamine was examined for antibacterial activity against Gram-positive and Gram-negative bacteria [1-2], but development was discontinued at Phase 2.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 5
Rotatable bonds 16
Topological polar surface area 142.29
Molecular weight 627.46
XLogP 6.34
No. Lipinski's rules broken 2
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES NCCCCNCCCN[C@H]1CC[C@]2([C@H](C1)C[C@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CC[C@H](C(C)C)OS(=O)(=O)O)C)C)O)C
Isomeric SMILES NCCCCNCCCN[C@H]1CC[C@]2([C@H](C1)C[C@H]([C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@H]2[C@@H](CC[C@H](C(C)C)OS(=O)(=O)O)C)C)O)C
InChI InChI=1S/C34H65N3O5S/c1-23(2)31(42-43(39,40)41)12-9-24(3)27-10-11-28-32-29(14-16-34(27,28)5)33(4)15-13-26(21-25(33)22-30(32)38)37-20-8-19-36-18-7-6-17-35/h23-32,36-38H,6-22,35H2,1-5H3,(H,39,40,41)/t24-,25-,26+,27-,28+,29+,30-,31-,32+,33+,34-/m1/s1
InChI Key UIRKNQLZZXALBI-MSVGPLKSSA-N
No information available.
Summary of Clinical Use Click here for help
Squalamine was advanced to clinical trial, for evaluation of anti-angiogenic activity for application in cancer therapy and for the treatment of neovascular age-related macular degeneration. As of May 2020, there are were active studies for these indications on ClinicalTrials.gov.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02727881 Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD Phase 3 Interventional Ohr Pharmaceutical Inc.
NCT00021385 Squalamine Lactate Plus Carboplatin in Treating Patients With Recurrent or Refractory Stage III or Stage IV Ovarian Cancer Phase 2 Interventional National Cancer Institute (NCI)
NCT00244920 Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer Phase 2 Interventional OHSU Knight Cancer Institute